



## BAD TO THE BONE

Peter Jones, Rheumatologist  
QE Health, Rotorua


GP CME Conference  
Rotorua, June 2008

## Agenda


- Osteoporosis in Men
- Vitamin D and Calcium
- Long-term treatment with Bisphosphonates




# Pathophysiology of Osteoporosis



# Bone Homeostasis



## Fractures are Common in Men




- At 60, lifetime risk of osteoporotic fracture is 25%
- One third of hip fractures occur in men
  - Hip or vertebra 6% vs 18%
  - Colles' 2.5% vs 16%

## Remaining Lifetime Risk of Fragility Fractures in the Swedish Population


Type of fracture	Lifetime risk at age 50 (%)	
	Women	Men
Hip	22.9	10.7
Distal forearm	20.8	4.6
Vertebrae (clinical)	15.1	8.3
Proximal humerus	12.9	4.1
Any of the above	46.4	22.4

## It's Good to be a Man

- Peak Bone Mass is Higher
  - Pubertal growth regulated by sex steroids
  - Higher ratio of cortical to cancellous bone
  - Greater BMD than women partly due to larger bone size



## Effect of Bone Geometry on Bone Strength



---

Cross-sectional area	1.0	1.0	1.0
Bending Strength	1.0	4.0	8.0
Axial Strength	1.0	1.7	2.3



These three cylinders have identical cross-sectional areas. Their bending strength is determined by the distance of their material from the axis. A larger bone (e.g. in a man) is much stronger than a smaller bone with the same mineral content.



## Men Are Different From Women

- Bone loss is less and later
  - No postmenopausal rapid decline in estrogen
  - No preferential cancellous bone loss
  - Different fracture patterns (forearm fractures rare)
- Fracture rates approximate women but 10 years later
- Fractures in Men indicate a much poorer health state


# Patterns of Bone Loss in Men and in Women



## Causes of Low Bone Mass in Men

- Low PBM
  - Constitutional delayed puberty
  - Primary hypogonadism
  - Androgen insensitivity
- Causes of increased bone loss
  - Alcohol
  - Prostate cancer
  - Androgen deprivation (orchidectomy, GnRH inhibitors)
  - Oestrogen deficiency (aromatase inhibitors)

## Bone Loss Due to Sex Steroid Deficiency in Men



- Bioavailable T and E<sub>2</sub> decline with normal aging
- Bone loss in men is best correlated with bioavailable E<sub>2</sub>
- Bioavailable E<sub>2</sub> is a determinant of bone mass in men, as in women

## Bone Loss in Men

- Bone loss accelerates after 70
- Mostly due to decreased formation
  - In women – due to loss of trabeculae
- 40-60% of osteoporotic men have secondary osteoporosis (Vs 5-10% of women)
  - Investigation has a higher yield of pathology
  - Mortality following hip fracture is higher (indicates frailty, poor health)
- Fractures can be predicted by
  - Fractures, especially radius
  - Low levels of physical activity in elderly men
  - Family history



## 'Causes' of Low BMD and Fractures in Men

- Idiopathic 40-60%
- Glucocorticoids
- Smoking
- Alcohol
- Hypogonadism
- Hypercalciuria
- Weight loss
- Low calcium intake
- Low levels of physical activity (especially in elderly)

## Treatment of Osteoporosis in Men

- Resistance training (increases BMD but no fracture data)
- Testosterone replacement
  - Works best for hypogonadal adolescents
  - Increases in BMD of 9% over 3 years in hypogonadal men >65
  - Increase in trabecular connectivity by MRI
  - Little evidence of benefit in eugonadal men
    - but significant harms
  - IM treatment more effective than transdermal in observational studies
- No role for androgen therapy

Ebeling, NEJM 2008; 358:1474-1482

## Fracture Risk Reduction in Osteoporosis

### Risk Factors

- Bone loss/low BMD
  - Calcium/D deficiency
  - Estrogen deficiency
- Tendency to fall
  - Muscle weakness
  - Poor balance

### Therapies

- Preserve/increase BMD
  - Calcium/D supplementation
  - Drug therapy
- Fall prevention
  - Strengthening exercises, vit D
  - Balance exercise

## Calcium and Vitamin D



## NICE guidelines: Secondary Prevention of Osteoporosis

- Bisphosphonates are recommended as first-line treatment options for the secondary prevention of fragility fractures
- Adequate levels of calcium and vitamin D required to ensure optimum effects of treatments for osteoporosis
- Calcium and/or vitamin D supplementation should be provided unless clinicians are confident that women who receive treatment have an adequate calcium intake and are vitamin D replete


**Adapted from National Institute for Clinical Excellence. January 2005.**

***Bisphosphonates, selective oestrogen receptor modulators and parathyroid hormone for the secondary prevention of osteoporotic fragility fractures in postmenopausal women.***

## Vascular Events in Healthy Older Women Receiving Calcium Supplementation (Bollard et al BMJ 2008;336:262-266)

- Primary prevention study over 5 years, 1471 postmenopausal women, mean age 74
- Randomised to placebo or 1000mg/d Ca as citrate
- Outcomes
  - Fractures
  - Deaths, sudden deaths, MI, angina, stroke, TIA
  - Composite endpoint: MI, stroke, sudden death
- Rationale
  - Ca supplements increase HDL:LDL ratio
  - Some evidence that Ca reduces cardiac events

## Calcium and Heart Disease



Kaplan-Meier survival plot showing proportion of healthy postmenopausal women assigned to calcium supplementation or to placebo that had a verified myocardial infarction during the study. Included are events self reported by participants and those from the national database of hospital admissions and review of death certificates ( $P=0.14$  when compared by log rank test)

## Calcium and Heart Disease

**Table 3 | Verified vascular events self-reported by healthy postmenopausal women assigned to calcium supplementation or to placebo or reported by family members. Values are numbers of women (numbers of events) unless stated otherwise**

Vascular event	Calcium group (n=732)	Placebo group (n=739)	P value*	Relative risk (95% CI)
Myocardial infarction	21 (24)	10 (10)	0.047	2.12 (1.01 to 4.47)
Stroke	31 (34)	22 (23)	0.21	1.42 (0.83 to 2.43)
Sudden death	3	3	1.0	1.01 (0.20 to 4.99)
Myocardial infarction, stroke, or sudden death	51 (61)	35 (36)	0.076	1.47 (0.97 to 2.23)

\*Differences between groups in numbers of women with reported events, based on Fisher's exact test.

**“the present study does not unequivocally show an adverse cardiovascular effect of calcium ... this matter needs to be considered carefully”**


## What to Advise Patients About Calcium

- You need some calcium to maintain bone health
  - If you have osteoporosis the need is greater
  - All drug trials of osteoporosis supplement calcium
- Aim for 1000mg – 1200mg from all sources
  - Supplement if necessary 500-1000mg/day
- High doses of calcium may be harmful if you have a high cardiovascular risk
  - High doses were used in the study
  - Elderly patients were enrolled
- Vitamin D can compensate for low calcium intake


## Vitamin D: The Sunshine Vitamin



# Vitamin D Metabolism





## Actions of Vitamin D




## Vitamin D: How Much is Enough?

PTH reaches a plateau at 25(OH)D >31.0 ng/mL

Inverse correlation between PTH and 25(OH)D;  $r = -0.290$ ,  $p < 0.001$




# Vitamin D and Muscle Function



# Vitamin D Prevents Falls: Meta-analysis

Source	Odds Ratio (95% CI)
Pfeifer et al, 2000	0.47 (0.20-1.10)
Bischoff et al, 2003	0.68 (0.30-1.54)
Gallagher et al, 2001	0.53 (0.32-0.88)
Dukas et al, 2004	0.69 (0.41-1.16)
Graafmans et al, 1996	0.91 (0.59-1.40)
Pooled (Uncorrected)	0.69 (0.53-0.88)




## Vitamin D Supplements and Fracture Risk

- Five-year randomized, double-blind, controlled trial
- n = 2686      Age 65–85
- Vitamin D = 100,000 IU once every four months (equivalent to 800 IU/day)
- Men (75.8%) and women living in the community

### Post Rx Vitamin D status


	n (%)	25 OH D
PBO	114 (4.4)	23.5 ng/ml
Vit D	124 (4.6)	39.7 ng/ml



Trivedi, et al. BMJ 2003;326:469-472


## Alendronate + D: Efficacy Study Design

Winter, No vitamin D supplements or unprotected sunlight exposure



## Alendronate + D and Vitamin D Status

Patients treated with Alendronate + D maintained vitamin D levels during the winter






## Long-Term Treatment With Bisphosphonates


- Who To Treat?
- How Effective?
- What happens when you stop?

## Fracture Rates, Population BMD Distribution and Number of Fractures in NORA



Siris, E. S., et al. Arch Intern Med 2004 164:1108-12, with permission. Copyright © 2004 American Medical Association

## Ten year risk of hip fracture - Swedish women




Low BMD  
Age  
High bone turnover  
Falls  
Poor visual acuity  
Previous fragility Fx  
Glucocorticoids  
FH of hip fracture  
Low BMI  
Cigarette smoking  
Excess alcohol

## WHO Fracture Risk Assessment Tool

- 10-year probability of fracture based on
  - age, sex, BMI (height and weight), prior fragility fractures, parental history of hip fracture, long-term oral glucocorticoids, cigarette smoking, alcohol (3 units daily) and rheumatoid arthritis
- Validated in 11 Countries (in women)
- Now published and available on-line
  - <http://www.shef.ac.uk/FRAX/index.htm>

# FRAX Online Fracture Risk Assessment Tool




**FRAX™** WHO Fracture Risk Assessment Tool

HOME   CALCULATION TOOL   PAPER CHARTS   FAQ   REFERENCES   Select a Language ▾

## Calculation Tool

Please answer the questions below to calculate the ten year probability of fracture with BMD.



Country : **UK**   Name / ID :    [About the risk factors](#) ⓘ

**Questionnaire:**

1. Age (between 40-90 years) or Date of birth  
Age:    Date of birth: Y:  M:  D:

2. Sex    Male    Female

3. Weight (kg)  

4. Height (cm)  

5. Previous fracture    No    Yes

6. Parent fractured hip    No    Yes

7. Current smoking    No    Yes

8. Glucocorticoids    No    Yes

9. Rheumatoid arthritis    No    Yes

10. Secondary osteoporosis    No    Yes

11. Alcohol 3 more units per day    No    Yes

12. Femoral neck BMD  
T-score ▾

**Weight Conversion:**  
pound:

**Height Conversion:**  
inch:



# Who To Treat

**FRAX™ WHO Fracture Risk Assessment Tool**

HOME   CALCULATION TOOL   PAPER CHARTS   FAQ   REFERENCES   Select a Language ▾

## Calculation Tool

Please answer the questions below to calculate the ten year probability of fracture with BMD.

 Country : **UK**   Name / ID :    About the risk factors 

**Questionnaire:**

1. Age (between 40-90 years) or Date of birth  
Age:    Date of birth: Y:  M:  D:

2. Sex    Male    Female

3. Weight (kg)  

4. Height (cm)  

5. Previous fracture    No    Yes

6. Parent fractured hip    No    Yes

7. Current smoking    No    Yes

8. Glucocorticoids    No    Yes

9. Rheumatoid arthritis    No    Yes


10. Secondary osteoporosis    No    Yes

11. Alcohol 3 more units per day    No    Yes

12. Femoral neck BMD   T-score ▾

**BMI 22.0**

The ten year probability of fracture (%) 

**with BMD**

■ Major osteoporotic	<b>26</b>
■ Hip fracture	<b>5.4</b>

**Weight Conversion:**  
pound:

**Height Conversion:**  
inch:

## Who To Treat

- Compared with treatment based on T scores
  - some patients do not need treatment even if  $T < -3$  (eg younger patients, absence of risk indicators for fracture)
  - some patients with  $T > -3$  have a high risk of fracture (other risk indicators for fracture are present)
- Treatment thresholds based on cost-utility analysis: UK
  - 20% 10 yr risk of osteoporotic fracture
  - 5% 10 yr risk of hip fracture
- Caveats
  - Risk assessment tool is a guide only, risk cutoffs are arbitrary
  - Not applicable to those who have been treated

## Fracture Risk Reduction in Osteoporosis


### Risk Factors

- Bone loss/low BMD
  - Calcium/D deficiency
  - Estrogen deficiency
- Tendency to fall
  - Muscle weakness
  - Poor balance

### Therapies


- Preserve/increase BMD
  - Calcium/D supplementation
  - Drug therapy
- Fall prevention
  - Strengthening exercises, vit D
  - Balance exercise

# Effect of Alendronate on Hip BMD over 5 years The FIT Study



# Effect of Stopping Alendronate on Total Hip BMD

## The FLEX Study



## Duration of Bisphosphonate Therapy

- “Drug holiday” after 5 years treatment if good response:
  - + 3-5% increase in hip BMD, 8-10% at lumbar spine
  - T Score above -2.5
  - Not at increased risk of vertebral fractures
  - Resume if rapid bone loss  
(-8% at 1yr, -10% at 2yr, -5% Pre-treatment)
- Continue treatment
  - High risk of vertebral fractures  
(prevalent vertebral fractures, T Score <2.5)

## Summary

- Osteoporosis is an important issue in men
  - Investigate as causes often present
- Vitamin D is important
  - Effect on falls as well as fractures
- Calcium supplements are still important
  - Consider CV risk
- Fracture Risk Assessment should guide treatment decisions not just T scores
- Long term use of bisphosphonates
  - Consider a drug holiday after 5 years